News
Regeneron Reports Promising Phase 3 Results for Cemdisiran in Generalized Myasthenia Gravis
Pune, India | August 29, 2025– Regeneron Pharmaceuticals has released promising Phase 3 trial results for cemdisiran. This investigational RNA interference (RNAi) therapy targets generalized
Read More